A Study of the Use of Pembrolizumab (MK-3475) in Patients with Relapsed or Hard to Treat Classical Hodgkin Lymphoma

Overview

About this study

The purpose of this study is to use pembrolizumab for patients with relapsed or hard to treat classical Hodgkins Lymphoma. The primary study hypothesis is that treatment with single agent pembrolizumab will result in a clinically meaningful overall response rate.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria 

  • Newly relapsed or refractory classical Hodgkins Lymphoma 
  • Participant may have failed to achieve a response to, progressed after, or be ineligible for
    • Autologous stem cell transplant 
    • Treatment with brentuximab vedotin or may be brentuximab vedotin naïve 
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Measurable disease 
  • Adequate organ function

 

Exclusion Criteria

  • Diagnosis of immunosuppression
  • Receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medication 
  • Prior monoclonal antibody within 4 weeks prior to study Day 1 
  • Prior Chemotherapy, targeted small molecular therapy, or radiation therapy within 2 weeks prior to study Day 1 
  • Prior allogeneic hematopoietic stem cell transplantation 
  • Known clinically active central nervous system involvement 
  • Known additional malignancy that is progressing or requires active treatment 
  • Active autoimmune disease requiring systemic treatment in past 2 years 
  • Evidence of active, non-infectious pneumonitis

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Stephen Ansell, M.D., Ph.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

More information

Publications

Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions